Robert Bhatt

Robert Bhatt investigates renal cell carcinoma immunotherapy with a focus on combination checkpoint inhibitor regimens. His research has contributed to clinical trials establishing nivolumab plus ipilimumab and pembrolizumab plus axitinib as first-line standards in advanced clear cell RCC with superior outcomes over sunitinib. He has characterized predictive biomarkers for immunotherapy response in RCC including the IMDC risk model, gene expression signatures, and immune microenvironment features. His translational work explores mechanisms of primary and acquired resistance to combination immunotherapy in RCC and informs rational subsequent therapy strategies after checkpoint inhibitor progression.